Join
Live feed
·
PRReleasevia Quantisnow
Cadrenal Therapeutics Inc. logo

Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement

ByQuantisnow·Wall Street's wire, on your screen.
CVKD· Cadrenal Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CVKD (Cadrenal Therapeutics Inc.) and more on Quantisnow.